ArticleCancer medicine2016

Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.

Michele Malagola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.